RELAPSED NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma
Disease control OngoingThis early-stage study is testing the safety of combining two targeted cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or hasn't responded to at least two prior treatments. The main goal is to find the safest and most e…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Apr 02, 2026 00:41 UTC
-
Scientists test radiation boost to supercharge Cancer-Fighting cells
Disease control OngoingThis study is testing if adding a low dose of radiation therapy is safe and practical for patients before they receive a CAR-T cell treatment for B-cell lymphoma that has returned or not responded to other therapies. The goal is to see if this combination can improve outcomes for…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for patients Who've run out of options: experimental drug enters human testing
Disease control OngoingThis early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…
Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 12, 2026 13:51 UTC